Reported Earlier, Moderna Out-Licenses COVID-19 Patents in Japan, Secures Royalty on Sales, Financial Terms Undisclosed
Portfolio Pulse from Benzinga Newsdesk
Moderna has entered a non-exclusive out-licensing agreement for its COVID-19-related patents in Japan, securing an upfront payment and a low double-digit royalty on net sales of its COVID-19 product. Financial terms were not disclosed.
April 29, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's new licensing agreement in Japan for COVID-19 patents includes an upfront payment and royalties, enhancing its revenue prospects.
The agreement signifies a new revenue stream for Moderna from the Japanese market, which could positively impact its financial performance. The deal's non-exclusive nature suggests potential for more such agreements, further boosting optimism around Moderna's revenue prospects from its COVID-19 portfolio.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90